Introduction
============

Prostate cancer (PCa) is the most common as well as the third leading cause of cancer-related deaths among men in Western countries.[@b1-ott-10-3123] In previous decades, signifi-cant breakthroughs have been made in the diagnosis, treatment, and understanding of the genesis of PCa. However, advances in several areas, such as validated biomarkers in facilitating prostate-specific antigen screening, management of metastatic disease, and prognostic biomarkers to assist clinicians in predicting outcomes and decision making, still need to be made.[@b2-ott-10-3123] So far, numerous biomarkers, including the expression of the E 26 (ETS) family of fusion genes, and serine peptidase inhibitor Kazal type 1 (SPINK1) overexpression, have been discovered in PCa.

In 1983, Huhtala et al first identified SPINK1 in urine samples of patients with gynecological cancers, which suggested that it may have significance as a tumor marker.[@b3-ott-10-3123] Subsequently, SPINK1 was found to be abnormally expressed in solid tumors, including PCa.[@b4-ott-10-3123] As a result of this, further studies were devoted to investigating whether this peptide was associated with the prognosis of PCa. Thus, Tomlins et al performed an analysis of molecular subtypes of PCa using SPINK1 and ETS-related gene (ERG) to predict clinical outcomes, and demonstrated the significant prognostic role of SPINK1 in PCa subtypes;[@b5-ott-10-3123] however, conflicting findings have been reported. Some studies found significant associations between SPINK1 and clinical outcomes while others demonstrated insignificant or even contrary correlations.[@b5-ott-10-3123]--[@b9-ott-10-3123]

Therefore, we have conducted a systematic review and meta-analysis to evaluate the prognostic value of SPINK1 expression in patients with PCa. We have also assessed the current best evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

Materials and methods
=====================

Two researchers (XMZ and XXY) independently performed the searches, study selection, quality assessment, and data extraction of included studies. Disagreements were resolved by discussion or with the help of a third investigator (HZ).

Eligibility and exclusion criteria for study selection
------------------------------------------------------

The eligibility criteria included: 1) patients with pathologically confirmed PCa, 2) cohort or cross-sectional studies investigating the associations between SPINK1 and PCa clinical outcomes, and 3) no language restrictions for published studies. Exclusion criteria included reviews, reports that only focused on laboratory findings of expression profiles of SPINK1 without clinical prognostic outcome measures, and studies with only published abstracts.

Outcome measures included: 1) biochemical recurrence (BCR), 2) PCa-specific mortality (PCSM), 3) overall survival (OS), and 4) castration-resistant PCa (CRPC)-free survival. The definition of CRPC is provided in our previous study.[@b10-ott-10-3123]

Data resources and searches
---------------------------

Searches were made using PubMed (1950-2017.1), Med-line (1966-2017.1), Embase (1947--2017.1), and the China Biology Medicine disc (CBMdisc, 1978--2017.1). The following terms and keywords were used: "trypsin inhibitor, Kazal pancreatic", "SPINK1", "pancreatic secretory trypsin inhibitor", "PSTI", "tumor-associated trypsin inhibitor", "TATI", and "prostate cancer". References in selected studies were searched for more studies, and experts in the field were consulted.

Study selection and data extraction
-----------------------------------

Two investigators independently reviewed the titles and abstracts of the search results. The full text versions of studies, which were potentially eligible, were then assessed. Participant characteristics, experimental techniques, outcome measures, results, and other pertinent data of each included study were extracted and recorded on data extraction forms, which were designed according to the guidelines specified in the *Cochrane Handbook*.[@b11-ott-10-3123] We contacted authors to seek additional information where data were either not reported or not clear.

Assessment of risk of bias
--------------------------

Two reviewers (XMZ and XXY) independently assessed the risk of bias of included studies using the Newcastle--Ottawa Scale (NOS), which covers three main areas: selection, comparability, and outcome.[@b12-ott-10-3123] Each study was categorized as low risk of bias (\>7 score), moderate risk of bias (5--7 score), or high risk of bias (\<5 score).

Data synthesis
--------------

RevMan software (version 5.3) was used to perform meta-analysis. Hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were synthesized with fixed or random effects models depending on the degree of heterogeneity. A random effect model was used when significant heterogeneity was considered at *P*\<0.10 or *I*^2^\>50%.

Subgroup analysis was considered for the different groups of patients in the studies. Publication bias was assessed by creating a funnel plot using RevMan software. We applied GRADE approach to assess the quality of evidence recommended by the *Cochrane Handbook*. This approach specifies four levels of quality, ranging from high to moderate, low, and very low.[@b11-ott-10-3123]

Results
=======

Study characteristics
---------------------

Three hundred twenty-one studies were identified through electronic searches. One hundred one were excluded after duplicate publications. Full-texts of 38 studies were reviewed, and 13 published articles with 17,161 participants were finally included in the study ([Figure 1](#f1-ott-10-3123){ref-type="fig"}).[@b5-ott-10-3123]--[@b8-ott-10-3123],[@b13-ott-10-3123]--[@b21-ott-10-3123] Characteristics of the included studies are summarized in [Table 1](#t1-ott-10-3123){ref-type="table"}. All studies were retrospective cohorts published between 2008 and 2016, of which three were conducted in the USA,[@b5-ott-10-3123],[@b13-ott-10-3123],[@b17-ott-10-3123],[@b21-ott-10-3123] two in Germany,[@b14-ott-10-3123],[@b15-ott-10-3123] two in China,[@b16-ott-10-3123],[@b18-ott-10-3123] and one each in France,[@b6-ott-10-3123] Ireland,[@b7-ott-10-3123] Finland,[@b8-ott-10-3123] Korea,[@b19-ott-10-3123] and Canada.[@b20-ott-10-3123] Sample sizes ranged from 155 to 8,260. One study included patients with radical prostatectomy (RP) and/or transurethral resection of the prostate,[@b13-ott-10-3123] and two studies included metastatic PCa (mPCa).[@b8-ott-10-3123],[@b18-ott-10-3123] Overall, seven studies with nine cohorts investigated the associations between SPINK1 expression and clinical outcomes in patients with RP.[@b5-ott-10-3123]--[@b7-ott-10-3123],[@b14-ott-10-3123]--[@b17-ott-10-3123]

Assessment of risk of bias for included studies
-----------------------------------------------

According to the NOS, all included studies were of high quality with scores ranging from 7 to 9 (average 7.9). The most common source of bias was from outcome measures, for which most studies were unclear about the length or adequacy of follow-up ([Table 2](#t2-ott-10-3123){ref-type="table"}).

Associations between SPINK1 and clinical outcomes of PCa treated with RP
------------------------------------------------------------------------

As shown in [Figure 2A](#f2-ott-10-3123){ref-type="fig"}, a pooled analysis indicated that expression of SPINK1 was associated with poor BCR-free survival in patients with PCa, with a HR of 1.41 (95% CI: 1.01--1.97, *P*=0.04). No statistically significant associations were observed between SPINK1 expression and PCSM-free survival (HR =0.93, 95% CI: 0.33--2.57, *P*=0.88; [Figure 2B](#f2-ott-10-3123){ref-type="fig"}) and OS (HR =1.18, 95% CI: 0.55--2.52, *P*=0.67; [Figure 2C](#f2-ott-10-3123){ref-type="fig"}).

Associations between SPINK1 and clinical outcomes of mPCa
---------------------------------------------------------

For patients with metastatic disease, SPINK1 expression was significantly associated with CRPC-free survival (HR =3.87, 95% CI: 1.87--8.00, *P*=0.0003; [Figure 2D](#f2-ott-10-3123){ref-type="fig"}), indicating that CRPC-free survival was shorter in patients with SPINK1-positive than SPINK1-negative tumors. Subgroup analysis suggested that SPINK1 expression was associated with shorter PCSM in patients with mPCa (HR =2.6, 95% CI: 1.04--6.5; *P*=0.04). However, only one study reported this outcome in mPCa patients.[@b21-ott-10-3123] Because only one study investigated OS among mPCa patients, data synthesis could not be conducted.[@b18-ott-10-3123] However, this study demonstrated that SPINK1 expression was negatively associated with OS (HR =2.59, 95% CI: 1.16--5.78; *P*=0.02).

Publication bias
----------------

A funnel plot was used to assess the risk of publication bias. As shown in [Figure 3](#f3-ott-10-3123){ref-type="fig"}, clear asymmetry was uncovered in the plot, which meant we could not exclude publication bias. Potential reasons for funnel plot asymmetry might be variations in study size and delayed publication, among other factors. However, because of the limited studies included in the analysis, it was difficult to obtain verification for this.

Quality of evidence by GRADE approach
-------------------------------------

As shown in [Table 3](#t3-ott-10-3123){ref-type="table"}, the quality of the evidence for BCR-free, PCSM-free, CRPC-free, and OS was graded as very low in all instances. Serious inconsistencies were observed for BCR-free survival measures. Serious risk of bias, inconsistency, and imprecision were observed for PCSM- and CRPC-free survival outcomes as well. Finally, for OS, serious imprecision was found in both RP-treated and metastatic patients, and serious risk of bias was found in patients with metastatic disease.

Discussion
==========

This is the first systematic review and meta-analysis to evaluate the association between SPINK1 and prognosis of patients with PCa. In general, we included 13 cohort studies involving 17,161 patients. There were nine studies with 11 cohorts that reported BCR-free survival among men treated with RP. For PCSM-free survival, four studies were included in the final pooled analysis for RP patients and one for mPCa. However, only two studies reported CRPC-free survival and three studies reported OS. Eventually, we found that among patients treated with RP, SPINK1 was associated with BCR-free survival, but not PCSM-free survival or OS. In patients with metastatic disease, the associations were statistically significant between SPINK1- and CRPC-free survival and OS; however, both outcomes only included one study each. Although overall and cancer-specific survival were hard to evaluate, we still found a trend for an unfavorable role of SPINK1 in disease progression.

We noticed that the significant associations between clinical outcomes and SPINK1 expression were more prominent among patients with mPCa. The distinction between metastatic and nonmetastatic disease implied that SPINK1 might have different roles at different stages of PCa progression. In 2015, Huang et al found that SPINK1 was upregulated at primary sites of patients with nodal mPCa.[@b20-ott-10-3123] Furthermore, knockdown of SPINK1 in vitro could inhibit cell invasion but not proliferation. This finding might explain why SPINK1 was associated with adverse prognosis in aggressive prostate tumors, as opposed to less or no association with clinical outcomes in patients with less aggressive tumors. However, these findings are not conclusive because of the limited number of studies and small sample sizes reported in patients with metastatic disease. Further explorations of SPINK1 in advanced PCa are needed to verify these conclusions.

Although more evident in metastatic diseases, SPINK1 may play a role in patients treated with RP. The insufficient value of SPINK1 as an independent prognostic factor suggests there is an essential need to incorporate it with other biomarkers. In 2015, Tomlins et al combined SPINK1 and ETS gene fusions (most commonly involving ERG) to stratify patients into different molecular subtypes based on risks of clinical outcomes.[@b5-ott-10-3123] Although the best evidence indicated that ERG alone had no association with BCR- or PCSM-free survival, the combination of ERG and SPINK1 was associated with Gleason scores.[@b22-ott-10-3123],[@b23-ott-10-3123]

The results of all studies included in this analysis were inconsistent. Therefore this meta-analysis was initiated to systematically assess these studies in the hope of understanding the real evidence for the prognostic role of SPINK1 in PCa. However, the differences among the included studies were too great to be conclusive. It is possible the disparities among these studies were as a result of issues with experimental, clinical, and/or statistical designs. The techniques and conditions for detecting the expression of SPINK1 in each study may also have been different. In addition, ethnicity, regional differences, and baseline characteristics of patients in the included studies might have contributed to the inconsistent results. Meanwhile, there were several limitations in our study. First, in the meta-analyses of all outcomes (BCR-, PCSM-, CRPC-free, and OS), significant heterogeneities were observed ([Figure 2](#f2-ott-10-3123){ref-type="fig"}). Heterogeneities could be derived from different sample sizes or follow-up lengths among studies. Next, the quality of the evidence evaluated by the GRADE approach was very low, resulting in conservative recommendations. Moreover, because of the inherent characteristic of the slow progressive nature of most PCa, it is difficult to obtain overall or PCa-specific survival in many studies. The analyses of CRPC-free survival and OS were restricted by the limited number of studies. More studies are needed to further investigate these outcomes. In addition, we were unable to extract eligible data for final analyses even in some studies that reported similar outcomes.

Most of the patients were treated with RP, and only a few had metastatic disease. It has been proven that biomarkers expressed at different disease sites or periods of disease progression might not reflect the current immune-active microenvironment. For instance, programmed death ligand-1 (PD-L1), a novel biomarker in PCa, is discordantly expressed in metastatic sites and primary tumors.[@b24-ott-10-3123],[@b25-ott-10-3123] Therefore, we believe it is necessary to further evaluate the association between SPINK1 expression and clinical outcomes in metastatic patients, especially the expression of SPINK1 in the metastatic site or stage.

Conclusion
==========

This is the first systematic review and meta-analysis to evaluate the association between SPINK1 and clinical outcomes among patients with PCa. We found that patients with SPINK1-positive PCa had shorter BCR-free survival (RP group), CRPC-free survival (mPCa), and OS (mPCa) than SPINK1-negative patients. SPINK1 was not a predictor of PCa mortality or OS among patients treated with RP. However, very low quality of evidence assessed by the GRADE approach suggests that high-quality data are necessary to further verify these conclusions.
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###### 

Characteristics of included studies

  --------------------------------------------------------------------------------------------------------------------------------------------
  Studies                            Patients     N       Country   Age (years)         PSA (ng/mL)       Gleason score   Follow-up (months)
  ---------------------------------- ------------ ------- --------- ------------------- ----------------- --------------- --------------------
  Tomlins et al[@b5-ott-10-3123]     RP/TURP      971     USA       NA                  NA                NA              NA

  Leinonen et al[@b8-ott-10-3123]    Endocrine\   186     Finland   +: 71.6±8.4\        +: 63±104\        \<7: 25.8%\     70 (2--118)
                                     Treated                        −: 73.8±6.8         −: 105±429        7: 29.0%\       
                                                                                                          \>7: 41.9%      

  Lippolis et al[@b14-ott-10-3123]   RP           3,385   Germany   ≤49: 2.9%\          \>4: 15.3%\       ≤3+3: 38.8%\    65.8 (1--219)
                                                                    50--60: 26.0%\      4--10: 55.8%\     3+4: 46.4%\     
                                                                    60--70: 63.8%\      10--20: 21.1%\    4+3: 11.6%\     
                                                                    \>70: 7.3%          \>20: 7.8%        ≥4+4: 3.2%      

  Grupp et al[@b15-ott-10-3123]      RP           8,260   Germany   \<50: 2.9%\         \<4: 12.6%\       ≤3+3: 25.6%\    36.8 (1--228)
                                                                    50--60: 24.8%\      4--10: 60.4%\     3+4: 14.0%\     
                                                                    60--70: 58.7%\      10--20: 19.4%\    4+3: 55.4%\     
                                                                    \>70: 12.9%         \>20: 6.5%        ≥4+4: 4.3%      

  Wang et al[@b16-ott-10-3123]       RP           211     China     ≤70: 70.6%\         \<4: 10.4%\       \<7: 21.8%\     NA
                                                                    \>70: 29.4%         4--10: 12.8%\     7: 33.2%\       
                                                                                        \>10: 76.8%       \>7: 45.0%      

  Flavin et al[@b7-ott-10-3123]      RP           854     Ireland   65.4±6.0            7.0±5.6           2--6: 21.0%\    13.5±4.6
                                                                                                          3+4: 37.0%\     
                                                                                                          4+3: 24.3%\     
                                                                                                          8--10: 17.6%    

  Brooks et al[@b17-ott-10-3123]     RP           963     USA       61.7±7.2            8.7±8.8           \<7: 94.0%\     NA
                                                                                                          3+4: 40.2%\     
                                                                                                          4+3: 12.5%\     
                                                                                                          \>7: 10.1%      

  Terry et al[@b6-ott-10-3123]       RP           279     France    64.1 (44.2--75.2)   13.5 (1.3--119)   \<7: 43.0%\     50.1 (1--190.5)
                                                                                                          3+4: 13.7%\     
                                                                                                          4+3: 18.8%\     
                                                                                                          \>7: 24.6%      

  Tomlins et al[@b13-ott-10-3123]    RP           1,577   USA       63 (37.3--83)       \<10: 47.2%\      ≤6: 16.2%\      NA
                                                                                        10--20: 19.7%\    7: 56.3%\       
                                                                                        \>20: 15.6%\      8: 12.1%\       
                                                                                        NA: 20.3%         ≥9: 17.9%\      
                                                                                                          NA: 0.3%        

  Pan et al[@b18-ott-10-3123]        mPCa         155     China     72.6±7.9            70.2±35.4         \<7: 5.8%\      38.0 (6--63)
                                                                                                          3+4: 8.4%\      
                                                                                                          4+3: 26.5%\     
                                                                                                          \>7: 59.4%      

  Noh et al[@b19-ott-10-3123]        RP           64      Korea     +: 66.9±5.5\        +: 8.8±6.9\       \<7: 27.9%\     49.2 (11--111)
                                                                    −: 63.9±5.3         −: 13.2±10.0      7: 52.9%\       
                                                                                                          \>7: 19.1%      

  Huang et al[@b20-ott-10-3123]      RP           178     Canada    NA                  NA                \<7: 31.1%\     42.0 (0--142)
                                                                                                          7: 56.1%\       
                                                                                                          \>7: 12.7%      

  Johnson et al[@b21-ott-10-3123]    mPCa         60      USA       +: 60 (46--71)\     \<10: 56.7%\      ≤6: 37.4%\      48.0 (24--84)
                                                                    −: 59 (40--71)      10--20: 30.2%\    7: 46.2%\       
                                                                                        \>20: 12.1%       8: 12.9%\       
                                                                                                          ≥9: 4.4%        
  --------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** For age and PSA, data were represented as mean ± SD, mean (range), or percentage. Follow-up was presented as median (range) or mean ± SD.

**Abbreviations:** PSA, prostate specific antigen; mPCa, metastatic prostate cancer; NA, not available; RP, radical prostatectomy; SD, standard deviation; TURP, transurethral resection of prostate; +, SPINK1 positive; −, SPINK1 negative.

###### 

Risk of bias for included studies

  Studies                            Year   Selection   Comparability   Outcome   Total                    
  ---------------------------------- ------ ----------- --------------- --------- ------- ---- --- --- --- ---
  Tomlins et al[@b5-ott-10-3123]     2008   ★           ★               ★         ★       ★★   ★   ★   ✰   8
  Leinonen et al[@b8-ott-10-3123]    2010   ★           ★               ★         ★       ★★   ★   ✰   ✰   7
  Lippolis et al[@b14-ott-10-3123]   2013   ★           ★               ★         ★       ★★   ★   ★   ✰   8
  Grupp et al[@b15-ott-10-3123]      2013   ★           ★               ★         ★       ★★   ★   ★   ✰   8
  Wang et al[@b16-ott-10-3123]       2014   ★           ★               ★         ★       ★★   ★   ✰   ✰   7
  Flavin et al[@b7-ott-10-3123]      2014   ★           ★               ★         ★       ★★   ★   ★   ★   9
  Brooks et al[@b17-ott-10-3123]     2015   ★           ★               ★         ★       ★★   ★   ✰   ✰   7
  Terry et al[@b6-ott-10-3123]       2015   ★           ★               ★         ★       ★★   ★   ★   ✰   8
  Tomlins et al[@b13-ott-10-3123]    2015   ★           ★               ★         ★       ★★   ★   ★   ✰   8
  Pan et al[@b18-ott-10-3123]        2016   ★           ★               ★         ★       ★★   ★   ★   ★   9
  Noh et al[@b19-ott-10-3123]        2016   ★           ★               ★         ★       ★★   ★   ★   ★   8
  Huang et al[@b20-ott-10-3123]      2016   ★           ★               ★         ★       ★★   ★   ★   ✰   8
  Johnson et al[@b21-ott-10-3123]    2016   ★           ★               ★         ★       ★★   ★   ★   ★   8

**Notes:** ➀ Representativeness of the exposed cohort; ➁ Selection of the nonexposed cohort; ➂ Ascertainment of exposure; ➃ Outcome not present at start; ➄ Assessment of outcome; ➅ Adequate follow-up length; ➆ Adequacy of follow-up. The solid star represented adequate illustration of the corresponding items. The hollow star represented the opposite.

###### 

Summary of findings of graded quality of evidence for all outcomes

  Quality assessment                                    No of participants (studies)   Relative effect (95% CI)   Quality       Importance                                                          
  ----------------------------------------------------- ------------------------------ -------------------------- ------------- ------------ -------------------- ---------------------- ---------- ----------
  **Biochemical recurrence-free survival**                                                                                                                                                          
  Not serious                                           Serious                        Not serious                Not serious   None         16,760 (9 studies)   HR 1.41 (1.01--1.97)   Very low   Critical
  **PCSM-free survival for radical prostatectomy**                                                                                                                                                  
  Serious                                               Serious                        Not serious                Serious       None         3,630 (4 studies)    HR 0.69 (0.21--2.25)   Very low   Critical
  **CRPC-free survival**                                                                                                                                                                            
  Serious                                               Serious                        Not serious                Serious       None         341 (2 studies)      HR 3.07 (0.98--9.63)   Very low   Critical
  **Overall survival for radical prostatectomy**                                                                                                                                                    
  Not serious                                           Not serious                    Not serious                Serious       None         1,972 (2 studies)    HR 0.89 (0.58--1.35)   Very low   Critical
  **Overall survival for metastatic prostate cancer**                                                                                                                                               
  Serious                                               Not serious                    Not serious                Serious       None         155 (1 study)        HR 2.59 (1.16--5.78)   Very low   Critical

**Abbreviations:** CI, confidence interval; CRPC, castration-resistant PCa; HR, hazard ratio; PCSM, prostate cancer-specific mortality.
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